These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 37120929)

  • 1. LPS-induced mitochondrial dysfunction regulates innate immunity activation and α-synuclein oligomerization in Parkinson's disease.
    Esteves AR; Silva DF; Banha D; Candeias E; Guedes B; Cardoso SM
    Redox Biol; 2023 Jul; 63():102714. PubMed ID: 37120929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal infection triggers mitochondria-mediated α-synuclein pathology: relevance to Parkinson's disease.
    D Magalhães J; Candeias E; Melo-Marques I; Silva DF; Esteves AR; Empadinhas N; Cardoso SM
    Cell Mol Life Sci; 2023 May; 80(6):166. PubMed ID: 37249642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Synuclein and mitochondria: partners in crime?
    Nakamura K
    Neurotherapeutics; 2013 Jul; 10(3):391-9. PubMed ID: 23512373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intramitochondrial proteostasis is directly coupled to α-synuclein and amyloid β1-42 pathologies.
    Lautenschläger J; Wagner-Valladolid S; Stephens AD; Fernández-Villegas A; Hockings C; Mishra A; Manton JD; Fantham MJ; Lu M; Rees EJ; Kaminski CF; Kaminski Schierle GS
    J Biol Chem; 2020 Jul; 295(30):10138-10152. PubMed ID: 32385113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease.
    Di Maio R; Barrett PJ; Hoffman EK; Barrett CW; Zharikov A; Borah A; Hu X; McCoy J; Chu CT; Burton EA; Hastings TG; Greenamyre JT
    Sci Transl Med; 2016 Jun; 8(342):342ra78. PubMed ID: 27280685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Endotoxin Hypothesis of Parkinson's Disease.
    Brown GC; Camacho M; Williams-Gray CH
    Mov Disord; 2023 Jul; 38(7):1143-1155. PubMed ID: 37157885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial dysfunction is a key pathological driver of early stage Parkinson's.
    Toomey CE; Heywood WE; Evans JR; Lachica J; Pressey SN; Foti SC; Al Shahrani M; D'Sa K; Hargreaves IP; Heales S; Orford M; Troakes C; Attems J; Gelpi E; Palkovits M; Lashley T; Gentleman SM; Revesz T; Mills K; Gandhi S
    Acta Neuropathol Commun; 2022 Sep; 10(1):134. PubMed ID: 36076304
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Magalhães JD; Candeias E; Melo-Marques I; Abreu AE; Pereira-Santos AR; Esteves AR; Cardoso SM; Empadinhas N
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A functional role for alpha-synuclein in neuroimmune responses.
    Heiden DL; Monogue B; Ali MDH; Beckham JD
    J Neuroimmunol; 2023 Mar; 376():578047. PubMed ID: 36791583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell biology of Parkinson's disease: Mechanisms of synaptic, lysosomal, and mitochondrial dysfunction.
    Brooker SM; Naylor GE; Krainc D
    Curr Opin Neurobiol; 2024 Apr; 85():102841. PubMed ID: 38306948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondria interaction networks show altered topological patterns in Parkinson's disease.
    Zanin M; Santos BFR; Antony PMA; Berenguer-Escuder C; Larsen SB; Hanss Z; Barbuti PA; Baumuratov AS; Grossmann D; Capelle CM; Weber J; Balling R; Ollert M; Krüger R; Diederich NJ; He FQ
    NPJ Syst Biol Appl; 2020 Nov; 6(1):38. PubMed ID: 33173039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Mobility Group Box 1 Protein: A Plausible Therapeutic Molecular Target in Parkinson's Disease.
    Goyal A; Agrawal A; Dubey N; Verma A
    Curr Pharm Biotechnol; 2024; 25(8):937-943. PubMed ID: 37670710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD.
    Esteves AR; Arduíno DM; Silva DF; Oliveira CR; Cardoso SM
    Parkinsons Dis; 2011 Jan; 2011():693761. PubMed ID: 21318163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation.
    Kline EM; Houser MC; Herrick MK; Seibler P; Klein C; West A; Tansey MG
    Mov Disord; 2021 Jan; 36(1):25-36. PubMed ID: 33314312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The systemic immune response in Parkinson's disease: focus on the peripheral immune component.
    Lauritsen J; Romero-Ramos M
    Trends Neurosci; 2023 Oct; 46(10):863-878. PubMed ID: 37598092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Immune Dysfunction in Parkinson's Disease Development.
    Cossu D; Hatano T; Hattori N
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central and peripheral innate and adaptive immunity in Parkinson's disease.
    Harms AS; Yang YT; Tansey MG
    Sci Transl Med; 2023 Nov; 15(721):eadk3225. PubMed ID: 37939158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A central role for mitochondrial-derived vesicles in the innate immune response: implications for Parkinson's disease.
    Ryan TA; Tumbarello DA
    Neural Regen Res; 2021 Sep; 16(9):1779-1780. PubMed ID: 33510074
    [No Abstract]   [Full Text] [Related]  

  • 19. Sleep regulates innate immunity.
    Dempsey LA
    Nat Immunol; 2024 Jan; 25(1):3. PubMed ID: 38168964
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of DRP1-dependent mitochondrial fission by Mdivi-1 alleviates atherosclerosis through the modulation of M1 polarization.
    Su ZD; Li CQ; Wang HW; Zheng MM; Chen QW
    J Transl Med; 2023 Jun; 21(1):427. PubMed ID: 37386574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.